| |
|
|
|
| |
 |
|
|
| |
Neurim Pharmaceuticals is a drug discovery and development company. Its first
approved drug, Circadin® – prolonged release melatonin for insomnia, has been
commercially available in the EU since October, 2007
|
|
|
 |
|
|
|
| |
|
|
| |
| |
|
|
 |
| |
| |
 |
|
|
|
|
Teva
Neurim Pharmaceutical and Teva Pharmaceutical Industries Ltd agreed That Teva will in-licensed the exclusive rights for Circadin® for the
treatment of primary insomnia in Israel and become a stratgic partner. Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company
specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva
is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
With more than a century of experience in the healthcare industry, the Company enjoys a firmly established international presence, operating through a
carefully tailored network of worldwide subsidiaries. Headquartered in Israel, above 80% of Teva's sales, which totaled US$11.1 billion in 2008, are in
North America and Europe. Teva has over 38,000 employees worldwide and production facilities in Israel, North America, Europe and Latin America.
Lundbeck
|
Neurim Pharmaceuticals Ltd and H. Lundbeck A/S announced that Lundbeck in-licensed the exclusive rights for Circadin® for the treatment of
primary insomnia for the majority of markets in Europe including the five major markets. Furthermore, Lundbeck holds the exclusive option to evaluate
commercialization in markets outside of Europe.
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the
treatment of psychiatric and neurological disorders. In 2006, the company’s revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6
billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com
|
 |
Nycomed
|
Nycomed will be marketing Circadin® in Belgium, Netherlands, Austria, Greece, the Baltic States, Norway, Sweden, Finland, Denmark, Iceland,
Switzerland, Luxembourg and Russia-CIS. The first launch is expected during fourth quarter 2007
Nycomed provides products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.The company
is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New
products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America,
Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.
Privately owned, the combined group had non-audited estimated annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million
(2006 results).
For more information visit www.nycomed.com
|
 |
Sigma
|
Neurim Pharmaceuticals Ltd. and Sigma Pharmaceuticals Ltd. announced on December 2009, a licensing agreement for Circadin - prolonged release melatonin for primary insomnia in Australia.
Sigma Pharmaceuticals Ltd. launched Circadin in Australia in 2010
Sigma Pharmaceuticals Limited (ASX:SIP) is a leading Australian manufacturer, wholesaler and distributor of
prescription, over-the-counter and generic pharmaceutical products to pharmacies
throughout Australia. Sigma was originally founded by two Melbourne pharmacists in 1912
and merged with Arrow Pharmaceuticals in December 2005. In 2008, Sigma acquired Orphan Australia which is dedicated to providing highly
specialized pharmaceuticals for the treatment of serious or life threatening conditions in Australia.
For more information visit www.sigmaco.com.au
|
 |
DKSH
|
Diethelm Limited is a member of the DKSH Group, which came into being following the mergers of three Swiss companies:
Diethelm, Keller, and SiberHegner in 2000 and 2002
Established in 1906 on the banks of Chao Phraya River, today the company is one of Thailand's leading business organizations, with annual sales of THB 98 billion in 2008. It has over 10,000 employees and a comprehensive network of 203 branches all across the country.
It is the largest marketing, distribution, and logistics service provider in Thailand.
For more information visit www.dksh.co.th
|
|
|
|
